• In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand in cancer diagnostics, and continued to contend with extensive infant formula-related litigation and a securities class action.
• At the same time, the company’s decade-high dividend yield, long record of consecutive quarterly payouts, and growing medical devices footprint contrast with heightened regulatory and legal pressures on its nutrition business.
• We’ll now examine how the Exact Sciences acquisition, with its integration complexity and short‑term dilution, may reshape Abbott’s investment narrative.

We’ve uncovered the 13 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.

Abbott Laboratories Investment Narrative Recap

To own Abbott today, I think you need to believe in its ability to compound value through medical devices and diagnostics while managing legal and regulatory overhangs in nutrition. The near term story now pivots on how smoothly Abbott integrates Exact Sciences, with short term EPS dilution and execution risk, while the most immediate threat remains extensive infant formula litigation and the related securities class action, which the latest news reinforces as a material legal and reputational issue.

The completion of the roughly US$21.00 billion Exact Sciences acquisition feels like the clearest swing factor tied to the current news flow, because it expands Abbott’s cancer diagnostics reach just as the market is reassessing its execution and growth profile. Q1 2026 results modestly ahead of expectations suggest the core business is holding up, but the integration complexity, valuation reset, and ongoing legal pressures could shape how quickly any potential benefits from cancer diagnostics are reflected in sentiment.

Yet behind Abbott’s long dividend record and cancer diagnostics expansion, investors should also be aware of the scope of its infant formula and securities litigation exposure…

Read the full narrative on Abbott Laboratories (it’s free!)

Abbott Laboratories’ narrative projects $59.7 billion revenue and $9.5 billion earnings by 2029. This implies 9.7% yearly revenue growth and an earnings increase of about $3.2 billion from $6.3 billion today.

Uncover how Abbott Laboratories’ forecasts yield a $118.64 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently see Abbott’s fair value between US$118.64 and about US$135.71, highlighting a fairly tight cluster of higher estimates. You may want to weigh those views against the legal and regulatory risks around infant formula and securities litigation that could influence how much of the devices and diagnostics potential actually reaches shareholders over time.

Explore 5 other fair value estimates on Abbott Laboratories – why the stock might be worth as much as 60% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Abbott Laboratories’ overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com